Clinical Trial Update: Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin [Phase 3]

View source ↗

Summary

Phase 3 trial comparing exenatide with twice-daily biphasic insulin aspart in adults with Type 2 diabetes mellitus on sulfonylurea and metformin; results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• EXENATIDE (EXENATIDE)
• Insulin aspart (insulin aspart)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2013-07-31